Mineralys Therapeutics (MLYS)

Executive Summary

Mineralys Therapeutics is a clinical-stage biopharmaceutical company pioneering selective aldosterone synthase inhibitors, targeting the renin-angiotensin-aldosterone system to address treatment-resistant hypertension and related cardio-renal-metabolic diseases. Its lead candidate, lorundrostat, has demonstrated efficacy in multiple Phase 2 trials across hypertension, chronic kidney disease (CKD), and obstructive sleep apnea (OSA). The company completed its IPO in February 2023 and operates with a lean, remote-first structure, positioning itself to capture a significant share of the ~20-30% of hypertensive patients uncontrolled on standard therapies. Lorundrostat’s differentiated mechanism and positive Phase 2 data de-risk its late-stage development, making Mineralys a compelling investment in the hypertension space.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 Hypertension Trial (LAUNCH-HTN) Top-Line Data75% success
• Q2 2026Phase 2 Obstructive Sleep Apnea Full Data Presentation90% success
• Q3 2026Phase 2 Chronic Kidney Disease Data at Medical Conference85% success